Treatment Trials

4 Clinical Trials for Various Conditions

Focus your search

      RECRUITING
      Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas
      Description

      This research is being done to assess the effectiveness and safety of acalabrutinib combined with lisocabtagene maraleucel (liso-cel) for people with relapsed/refractory aggressive B-cell lymphoma. This research study involves the study drug acalabrutinib in combination with lisocabtagene maraleuce

      Conditions
      Refractory Aggressive B-cell LymphomasRefractory B-Cell Non-Hodgkin LymphomaAggressive B-cell NHLDiffuse Large B-cell Lymphoma (DLBCL)De Novo or Transformed Indolent B-cell LymphomaDLBCL, Nos Genetic SubtypesT Cell/Histiocyte-rich Large B-cell LymphomaEBV-Positive DLBCL, NosPrimary Mediastinal [Thymic] Large B-cell Lymphoma (PMBCL)High-Grade B-Cell Lymphoma, NosC-MYC/BCL6 Double-Hit High-Grade B-Cell LymphomaGrade 3b Follicular LymphomaC-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma
      Talk to us
      RECRUITING
      Study of SGR-1505 in Mature B-Cell Neoplasms
      Description

      The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.

      Conditions
      Mature B-Cell NeoplasmNon Hodgkin LymphomaDLBCLWaldenstrom MacroglobulinemiaMALT LymphomaFollicular LymphomaPediatric-Type Follicular LymphomaIRF4 Gene RearrangementEBV-Positive DLBCL, NosBurkitt LymphomaPlasmablastic LymphomaHigh-grade B-cell LymphomaPrimary Cutaneous Follicle Center LymphomaPrimary Effusion LymphomaMantle Cell LymphomaDLBCL Germinal Center B-Cell TypePrimary Mediastinal Large B Cell LymphomaT-Cell/Histiocyte Rich LymphomaALK-Positive Large B-Cell LymphomaPrimary Cutaneous Diffuse Large B-Cell LymphomaSplenic Marginal Zone LymphomaChronic Lymphocytic LeukemiaNodal Marginal Zone LymphomaHHV8-Positive DLBCL, NosLymphoplasmacytic LymphomaDuodenal-Type Follicular Lymphoma
      Talk to us
      TERMINATED
      An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas
      Description

      A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas

      Conditions
      Epstein-Barr Virus Associated Lymphoproliferative DisorderEBV-Related PTLDEBV Related Non-Hodgkin's LymphomaEBV-Positive DLBCL, NOSEBV Associated LymphomaEBV Related PTCL, NOS
      Talk to us
      COMPLETED
      Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies
      Description

      The purpose of this study is to determine the safety and tolerability of intravenous (IV) and subcutaneous (SC) administration of XmAb13676 and to determine the maximally tolerated dose (MTD) and/or recommended dose (RD).

      Conditions
      B-cell Non-Hodgkins LymphomaChronic Lymphocytic Leukemia
      Talk to us